Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 14/20 | 0.39 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 12/20 | 0.36 |
| ▸ | USP9X | Q93008 | 1/20 | 0.35 |
| ▸ | SLC9A5 | Q14940 | 1/20 | 0.33 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.33 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | ITGAL | P20701 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19690338 | 1.00 | MTNR1B (0.39) | MTNR1BSLC9A1MTNR1AUSP9XSLC9A5 | |
| SCHEMBL31561726 | 0.85 | MTNR1B (0.41) | MTNR1BSLC9A1MTNR1ASLC9A5SLC9A2 | |
| SCHEMBL25108307 | 0.75 | USP9X (0.43) | MTNR1BSLC9A1MTNR1AUSP9XSLC9A5 | |
| SCHEMBL9910076 | 0.75 | HTR2C (0.39) | MTNR1BSLC9A1MTNR1ASLC9A5SLC9A2 | |
| SCHEMBL11329511 | 0.74 | MTNR1B (0.37) | MTNR1BSLC9A1MTNR1AUSP9XSLC9A5 | |
| SCHEMBL29793765 | 0.72 | HTR2A (0.41) | MTNR1BSLC9A1MTNR1ASLC9A5SLC9A2 | |
| SCHEMBL19682349 | 0.72 | SLC9A1 (0.37) | MTNR1BSLC9A1MTNR1ASLC9A5SLC9A2 | |
| SCHEMBL24469522 | 0.72 | HTR2A (0.41) | MTNR1BSLC9A1MTNR1ASLC9A5SLC9A2 | |
| SCHEMBL4447693 | 0.72 | HTR2A (0.41) | MTNR1BSLC9A1MTNR1ASLC9A5SLC9A2 | |
| SCHEMBL6192119 | 0.72 | MTNR1B (0.46) | MTNR1BSLC9A1MTNR1ASLC9A5SLC9A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944616-B2 | Processes for the preparation of Tasimelteon and intermediates thereof | APOTEX INC. (CA) | 2018-04-17 | — | — | US | disclosed |
| US-9944616-B2 | Processes for the preparation of Tasimelteon and intermediates thereof | APOTEX INC. (CA) | 2018-04-17 | — | — | US | disclosed |
| US-9944616-B2 | Processes for the preparation of Tasimelteon and intermediates thereof | APOTEX INC. (CA) | 2018-04-17 | — | — | US | disclosed |
| US-20170355688-A1 | Processes for the Preparation of Tasimelteon and Intermediates Thereof | THE BANK OF NOVA SCOTIA (CA) | 2017-12-14 | — | — | US | disclosed |
| US-20170355688-A1 | Processes for the Preparation of Tasimelteon and Intermediates Thereof | THE BANK OF NOVA SCOTIA (CA) | 2017-12-14 | — | — | US | disclosed |
| US-20170355688-A1 | Processes for the Preparation of Tasimelteon and Intermediates Thereof | THE BANK OF NOVA SCOTIA (CA) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355688-A1 | Processes for the Preparation of Tasimelteon and Intermediates Thereof | TRMT1, SULT1A1, TMT1A | MTNR1B 1442/4885SLC9A1 2520/4885MTNR1A 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.